# Exosomes as the mechanism of mesenchymal stem cell brain repair in neonatal stroke

> **NIH NIH R21** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $444,125

## Abstract

Abstract
Neonatal (perinatal) arterial ischemic stroke is a major cause of long-term neurological and cognitive
deficits, including cerebral palsy and neurodevelopmental disabilities. While neonatal stroke is as
common as in the elderly, literature has emerged that the stage of brain development at the time of
stroke has a major impact on the pathophysiological mechanisms of brain damage. Previous
therapeutic efforts were mostly focused on protecting neurons acutely, but such strategies appeared to
be short-range. We reported that delayed intranasal administration of mesenchymal stem cells (MSC)
protects the white matter and improves long-term functional outcomes in an experimental model of a
transient middle cerebral artery occlusion (tMCAO) in neonatal rats. Extracellular vesicles (EV) are now
believed to play fundamental role in cell-cell communication without direct cell-cell contacts in healthy
and diseased organism and that EV is a part of neurodegenerative scenarios. Based on our preliminary
data that exosomes released from MSC (MSC-exo) protect neonatal brain following subacute stroke, in
this proposal we hypothesize that MSC-exo is the underlying mechanism of MSC-induced acute
neuroprotection and long-term recovery after neonatal stroke via modulation of microglial cell signaling.
Given that inflammation is a hallmark of perinatal brain injury, affecting both early injury and brain repair
and connectivity later in life, and that microglial cells contribute to neuro- and vasoprotection in neonatal
stroke, we will determine how uptake of untranasally administered MSC-exo by activated
microglia/macrophages in ischemic-reperfused regions affects neuroinflammation and injury in neonatal
mice of both sexes subjected to tMCAO and whether MSC-exo alter brain microenvironment via
release of microvesicles and small EV from microglia (Aim 1), and determine the long-term effects of
MSC-exo administration on myelination, brain repair and functional outcomes (Aim 2). To understand
the mechanistic role of MSC-exo and their therapeutic potential for neonatal stroke, we will utilize state-
of-the art experimental tools, including a clinically relevant perinatal focal arterial stroke model that we
invented, in conjunction with pharmacological approaches and advanced non-invasive imaging
methodologies (NanoSight, super resolution flow cytometry Alexa) and characterization of large/small
EV and their “cargo” released from microglia from injured regions. The significance and novelty of the
proposed studies are in advancing the mechanistic understanding of MSC-exo-induced cell-type
specific effects in neonatal brain after stroke and identifying novel therapeutic targets to create effective
and safe therapy for neonatal stroke.

## Key facts

- **NIH application ID:** 10373763
- **Project number:** 1R21NS120285-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Zinaida S Vexler
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $444,125
- **Award type:** 1
- **Project period:** 2021-09-15 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10373763

## Citation

> US National Institutes of Health, RePORTER application 10373763, Exosomes as the mechanism of mesenchymal stem cell brain repair in neonatal stroke (1R21NS120285-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10373763. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*